- The trend backdrop is active with a 21-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
GUD
TOR
Week ended 07 Aug 2026
Weekly Investor Report
Knight Therapeutics Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
9.76 CAD
-0.8%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 24.3% above the Trend Line and sits at 90.9% of its 52-week range. The latest completed week returned -0.8%, after a -0.4% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 54/100. Near-term considerations: price is close to its 52-week high.
Setup score
75
out of 100
Latest Close
9.76 CAD
7 Aug 2026
1W Return
-0.8%
latest completed week
4W Return
-0.4%
short-term follow-through
12W Return
15.8%
quarterly tape
Trend Breadth
55.8%
29 of 52 weeks active
Volume Ratio
2.2x
vs 13-week average
- 2 reversal markers appear in the recent smart-money tape.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-0.8%
Latest completed week; four-week move -0.4%.
Indicator stack
76/69
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
54/100
21 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 24.3% above the Trend Line and sits at 90.9% of its 52-week range. The latest completed week returned -0.8%, after a -0.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.2x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9212-week average 0.97
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.92Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -0.4% over four weeks, 15.8% over 12 weeks, and 54.2% over one year. The current trend has remained active for 21 consecutive weeks.
Performance by holding period
Active trend streak21 weeks
Active weeks in one year29
Trend breadth55.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.10Latest activity-pressure read.
Pressure change-6.9%Four-week change in activity pressure.
Leadership23.22Latest relative-leadership reading.
RS change-22.0%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength26/100Blend of value, momentum, and quality. Underlying universe rank 75; rank 1 is best.
Value30/100Relative valuation strength. Underlying universe rank 71; rank 1 is best.
Quality18/100Profitability and accounting quality. Underlying universe rank 83; rank 1 is best.
Momentum77/100Medium-term price momentum. Underlying universe rank 24; rank 1 is best.
Growth78/100Revenue and earnings growth. Underlying universe rank 23; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 82.7x Price divided by trailing earnings.
- Price / sales
- 2.0x Market value relative to trailing revenue.
- EV / EBITDA
- 12.3x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 6.6% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 44.8% Gross profit retained from each unit of revenue.
- Operating margin
- 1.6% Operating profit retained from revenue.
- Free-cash-flow margin
- 12.8% Free cash flow generated from revenue.
- Return on invested capital
- 0.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 21.2% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 633.4% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.0% Cash dividends relative to market value.
- Buyback yield
- 1.5% Net share repurchases relative to market value.
- Shareholder yield
- 1.5% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.5x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment54/100
Weighted news tone is neutral across 21 relevant articles.
5 positive · 16 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-4.0%Distance below the 52-week high.
13-week volatility3.6%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher15 of 2611 weeks finished lower.
Best week+15.1%Week of 8 May.
Worst week-3.0%Week of 15 May.
Latest week-0.8%Week of 7 Aug.
Shape of recent returns
Strong gains7
Modest gains8
Flat weeks0
Modest losses11
Sharp losses0
Recent vol3.6%13-week weekly-return volatility.
Base vol3.7%52-week weekly-return volatility.
Up/down split26/25Count of positive and negative weeks in the 52-week window.
Average skew3.3% / -1.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorCA Healthcare
4-week rank27 / 46
Group average0.0%
Trend breadth34.8%
Trend34.8%active weekly trend signals
MD47.8%positive activity pressure
RS23.9%positive relative leadership
Four-week leaders
IndustryCA Drug Manufacturers - Specialty & Generic
4-week rank14 / 21
Group average3.7%
Trend breadth42.9%
Trend42.9%active weekly trend signals
MD47.6%positive activity pressure
RS23.8%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape76/100
Trend, activity pressure, participation, and risk combine to a 76/100 tape read.
Indicator analysis86/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.92; 2 reversal markers Factors35/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 21; Small Cap Core rank 67 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment54/100Weighted news tone is neutral across 21 relevant articles.
Knight Therapeutics (TSX:GUD) Enters Sharper Healthcare Stocks Focus Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 9.76 CAD | -0.8% | 7.85 CAD | 6.05 CAD | 1.10 | 23.22 | 763.5K | On |
| 31 Jul 2026 | 9.84 CAD | 1.1% | 7.72 CAD | 6.01 CAD | 1.20 | 28.76 | 280.7K | On |
| 24 Jul 2026 | 9.73 CAD | -0.9% | 7.59 CAD | 5.98 CAD | 1.19 | 27.38 | 338.1K | On |
| 17 Jul 2026 | 9.82 CAD | 0.2% | 7.47 CAD | 5.95 CAD | 1.18 | 29.54 | 386.0K | On |
| 10 Jul 2026 | 9.80 CAD | -1.1% | 7.34 CAD | 5.92 CAD | 1.18 | 29.78 | 989.3K | On |
| 3 Jul 2026 | 9.91 CAD | 4.9% | 7.22 CAD | 5.89 CAD | 1.15 | 32.06 | 83.2K | On |
| 26 Jun 2026 | 9.45 CAD | 1.9% | 7.09 CAD | 5.85 CAD | 1.18 | 27.55 | 34.0K | On |
| 19 Jun 2026 | 9.27 CAD | -2.2% | 6.97 CAD | 5.83 CAD | 1.16 | 25.79 | 38.0K | On |
| 12 Jun 2026 | 9.48 CAD | 10.1% | 6.87 CAD | 5.80 CAD | 1.16 | 29.27 | 81.2K | On |
| 5 Jun 2026 | 8.61 CAD | 5.1% | 6.76 CAD | 5.77 CAD | 1.24 | 19.68 | 217.6K | On |
| 29 May 2026 | 8.19 CAD | -1.9% | 6.67 CAD | 5.74 CAD | 1.35 | 12.92 | 376.3K | On |
| 22 May 2026 | 8.35 CAD | -0.9% | 6.59 CAD | 5.72 CAD | 1.42 | 16.28 | 202.1K | On |
| 15 May 2026 | 8.43 CAD | -3.0% | 6.51 CAD | 5.70 CAD | 1.46 | 19.82 | 761.4K | On |
| 8 May 2026 | 8.69 CAD | 15.1% | 6.42 CAD | 5.68 CAD | 1.41 | 22.92 | 678.2K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.